CKD is developing non-hydroxamic acid (NHA)-based histone deacetylase 6 (HDAC6) inhibitors for non-oncology indications. CKD’s NHA inhibitors address the limitations of hydroxamic acid (HA ...

These include DNA methyltransferase and histone deacetylase (HDAC) inhibitors. Further candidates, including inhibitors of acetyl-lysine readers (bromodomain-containing proteins), are undergoing ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

(UC San Diego) Viracta Therapeutics announced the closure of a phase II trial of its combination therapy of the histone deacetylase inhibitor nanatinostat and the antiviral agent valganciclovir ...